166 related articles for article (PubMed ID: 30585038)
1. [Curative effects and influenced factors of EMA-CO as an initial regimen for the treatment of high-risk gestational trophoblastic neoplasia].
Liu W; Zhao W; Zhang YQ; Huang XF
Zhonghua Yi Xue Za Zhi; 2018 Dec; 98(47):3896-3899. PubMed ID: 30585038
[No Abstract] [Full Text] [Related]
2. [EMA/CO regimen for chemotherapy 24 patients with ultra high-risk gestational trophoblastic neoplasia].
Shen T; Chen LL; Qin JL; Wang XY; Cheng XD; Xie X; Lyu WG
Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):371-376. PubMed ID: 29961278
[No Abstract] [Full Text] [Related]
3. Relapsed or refractory gestational trophoblastic neoplasia treated with the etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EP-EMA) regimen.
Mao Y; Wan X; Lv W; Xie X
Int J Gynaecol Obstet; 2007 Jul; 98(1):44-7. PubMed ID: 17481633
[TBL] [Abstract][Full Text] [Related]
4. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy.
Escobar PF; Lurain JR; Singh DK; Bozorgi K; Fishman DA
Gynecol Oncol; 2003 Dec; 91(3):552-7. PubMed ID: 14675675
[TBL] [Abstract][Full Text] [Related]
5. High-risk metastatic gestational trophoblastic neoplasia. Primary management with EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy.
Cagayan MS
J Reprod Med; 2012; 57(5-6):231-6. PubMed ID: 22696818
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic evaluation of cisplatin, etoposide, and bleomycin chemotherapy regimen in high-risk gestational trophoblastic neoplasia].
Song SQ; Zhang GN
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):571-6. PubMed ID: 23141175
[TBL] [Abstract][Full Text] [Related]
7. Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy.
Lurain JR; Singh DK; Schink JC
J Reprod Med; 2006 Oct; 51(10):767-72. PubMed ID: 17086804
[TBL] [Abstract][Full Text] [Related]
8. Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia.
Turan T; Karacay O; Tulunay G; Boran N; Koc S; Bozok S; Kose MF
Int J Gynecol Cancer; 2006; 16(3):1432-8. PubMed ID: 16803542
[TBL] [Abstract][Full Text] [Related]
9. EMA-CO chemotherapy for high-risk gestational trophoblastic neoplasia: a clinical analysis of 54 patients.
Lu WG; Ye F; Shen YM; Fu YF; Chen HZ; Wan XY; Xie X
Int J Gynecol Cancer; 2008; 18(2):357-62. PubMed ID: 17711444
[TBL] [Abstract][Full Text] [Related]
10. EP-EMA regimen (etoposide and cisplatin with etoposide, methotrexate, and dactinomycin) in a series of 18 women with gestational trophoblastic neoplasia.
Han SN; Amant F; Leunen K; Devi UK; Neven P; Vergote I
Int J Gynecol Cancer; 2012 Jun; 22(5):875-80. PubMed ID: 22635033
[TBL] [Abstract][Full Text] [Related]
11. Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia.
Lurain JR; Schink JC
J Reprod Med; 2012; 57(5-6):219-24. PubMed ID: 22696816
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy for gestational trophoblastic neoplasia patients with a FIGO score of 12 or greater: A multistudy analysis.
Li J; Yue H; Wang X; Chen R; Lu X
Eur J Obstet Gynecol Reprod Biol; 2019 Jul; 238():164-169. PubMed ID: 31136884
[TBL] [Abstract][Full Text] [Related]
13. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis.
Alifrangis C; Agarwal R; Short D; Fisher RA; Sebire NJ; Harvey R; Savage PM; Seckl MJ
J Clin Oncol; 2013 Jan; 31(2):280-6. PubMed ID: 23233709
[TBL] [Abstract][Full Text] [Related]
14. Low-risk gestational trophoblastic neoplasia outcome after treatment with VMP regimen from 2005 to 2017.
Zhu CC; Liu HY; Wei Y; Shen Z; Qian LL; Song WG; Wang J; Wu DB; Zhang XF; Zhou Y
Taiwan J Obstet Gynecol; 2019 May; 58(3):332-337. PubMed ID: 31122520
[TBL] [Abstract][Full Text] [Related]
15. Gestational trophoblastic neoplasia: treatment outcomes from a single institutional experience.
Al-Husaini H; Soudy H; Darwish A; Ahmed M; Eltigani A; Edesa W; Elhassan T; Omar A; Elghamry W; Al-Hashem H; Al-Hayli S; Madkhali I; Ahmad S; Al-Badawi IA
Clin Transl Oncol; 2015 May; 17(5):409-15. PubMed ID: 25398721
[TBL] [Abstract][Full Text] [Related]
16. Changes in the management of high-risk gestational trophoblastic neoplasia in the National Trophoblastic Disease Center of Hungary.
Fülöp V; Szigetvári I; Szepesi J; Végh G; Berkowitz RS
J Reprod Med; 2014; 59(5-6):227-34. PubMed ID: 24937962
[TBL] [Abstract][Full Text] [Related]
17. Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasia.
Even C; Pautier P; Duvillard P; Floquet A; Kerbrat P; Troalen F; Rey A; Balleyguier C; Tazi Y; Leary A; Augereau P; Morice P; Droz JP; Fizazi K; Lhommé C
Eur J Cancer; 2014 Aug; 50(12):2082-9. PubMed ID: 24910417
[TBL] [Abstract][Full Text] [Related]
18. Conservative Chemotherapy in Gestational Trophoblastic Disease: Experience With Etoposide, Methotrexate, and Dactinomycin Chemotherapy.
Byun SW; Park TC; Bae SN
Int J Gynecol Cancer; 2016 May; 26(4):790-5. PubMed ID: 27057813
[TBL] [Abstract][Full Text] [Related]
19. [Impact of chemotherapy on ovarian function and quality of life of patients with gestational trophoblastic neoplasia].
Xue W; Yang JJ; Zhao J; Ren T; Feng FZ; Wan XR; Xiang Y
Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):377-383. PubMed ID: 29961279
[No Abstract] [Full Text] [Related]
20. Results with Floxuridine, Actinomycin D, Etoposide, and Vincristine in Gestational Trophoblastic Neoplasias with International Federation of Gynecology and Obstetrics Scores ≥5.
Li Y; Kong Y; Wan X; Feng F; Ren T; Zhao J; Yang J; Xiang Y
Oncologist; 2021 Dec; 26(12):e2209-e2216. PubMed ID: 34396643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
